Caregiver preferences for the treatment of males with fragile X syndrome

Journal of Developmental and Behavioral Pediatrics

Volumn 37, Issue 1, 2016, Pages 71-79

  Cross, James ^a   Yang, Jui Chen ^b   Johnson, F Reed ^c   Quiroz, Jorge ^d   Dunn, Judith ^d   Raspa, Melissa ^e   Bailey, Donald B ^e  

^a Medivation Inc   (United States)

^b Pacific Economic Research   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Roche Innovation Center New York   (United States)

^e RTI INTERNATIONAL   (United States)

Author keywords

Caregivers; Developmental disabilities therapy; Discrete choice experiment; Fragile X syndrome; Fragile X syndrome therapy; Patient preference

Indexed keywords

ADOLESCENT; ADULT; CAREGIVER; CHILD; FEMALE; FRAGILE X SYNDROME; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SELF CARE; SELF CONTROL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; CAREGIVERS; CHILD; CHILD, PRESCHOOL; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SELF CARE; SELF-CONTROL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84952631973     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0000000000000234     Document Type: Article

References (35)

1. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991;67:1047-1058.
2. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905-914.
3. Pieretti M, Zhang FP, Fu YH, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66:817-822.
4. Turner G, Robinson H, Laing S, et al. Population screening for fragile X. Lancet. 1992;339:1210-1213.
5. Berry-Kravis E, Grossman AW, Crnic LS, et al. Understanding fragile X syndrome. Curr Paediatr. 2002;12:316-324.
6. Bailey DB, Raspa M, Olmsted M, et al. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146A: 2060-2069.
7. Bailey DB Jr, Raspa M, Bishop E, et al. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: U.S. survey. J Dev Behav Pediatr. 2012;33:62-69.
8. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123:378-390.
9. Bagni C, Tassone F, Neri G, et al. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012; 122:4314-4322.
10. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl). 2013;2321:1237-1250.
11. Ghosh A, Michalon A, Lindemann L, et al. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat Rev Drug Discov. 2013;12:777-790.
12. Berry-Kravis E, Hessl D, Abbeduto L, et al. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013;34: 508-522.
13. Gonzalez JM, Johnson FR, Runken MC, et al. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013;53:1635-1650.
14. Gan TJ, Lubarsky DA, Flood EM, et al. Patient preferences for acute pain treatment. Br J Anaesth. 2004;92:681-688.
15. Ryan M, McIntosh E, Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ. 1998;7: 373-378.
16. Bryan S, Buxton M, Sheldon R, et al. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ. 1998;7:595-603.
17. Hauber AB, Mohamed AF, Johnson FR, et al. Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. Qual Life Res. 2014;23: 1813-1821.
18. Huber J, Zwerina K. The importance of utility balance and efficient choice designs. J Mark Res. 1996;33:307-317.
19. Kanninen B. Optimal design for multinomial choice experiments. J Mark Res. 2002;39:214-227.
20. Dey A. Orthogonal Fractional Factorial Designs. New York: Halstead Press; 1985.
21. Kuhfeld W. Marketing Research Methods in SAS: Experimental Design, Choice, Conjoint, and Graphical Techniques. Cary, NC: SAS Institute Inc; 2010.
22. Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3-13.
23. Train K. Discrete Choice Methods with Simulation. Cambridge, UK: Cambridge University Press; 2003.
24. Scarpa R, Alberini A. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht, Netherlands: Springer; 2005.
25. American Association for Public Opinion Research. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 7th ed. Deerfield, IL: American Association for Public Opinion Research; 2011.
26. American Association for Public Opinion Research. AAPOR Report on Online Panels. Deerfield, IL: American Association of Public Opinion Research; 2010.
27. Fryns JP. The fragile X syndrome. A study of 83 families. Clin Genet. 1984;26:497-528.
28. Bacalman S, Farzin F, Bourgeois JA, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67:87-94.
29. Symons FJ, Byiers BJ, Raspa M, et al. Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey. Am J Intellect Dev Disabil. 2010;115:473-481.
30. Arron K, Oliver C, Moss J, et al. The prevalence and phenomenology of self-injurious and aggressive behaviour in genetic syndromes. J Intellect Disabil Res. 2011;55:109-120.
31. Bailey DB Jr, Raspa M, Bishop E, et al. Health and economic consequences of fragile X syndrome for caregivers. J Dev Behav Pediatr. 2012;33:705-712.
32. Tranfaglia MR. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci. 2011;33:337-348.
33. Sparrow SS, Cicchetti DV. Diagnostic uses of the Vineland adaptive behavior scales. J Pediatr Psychol. 1985;10:215-225.
34. Aman MG, Burrow WH, Wolford PL. The aberrant behavior checklist-community: factor validity and effect of subject variables for adults in group homes. Am J Ment Retard. 1995; 100:283-292.
35. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28-37.